India · Delayed Price · Currency is INR Anuh Pharma Statistics
Total Valuation
Anuh Pharma has a market cap or net worth of INR 8.25 billion. The enterprise value is 7.46 billion.
| Market Cap | 8.25B |
| Enterprise Value | 7.46B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Aug 5, 2026 |
Share Statistics
Anuh Pharma has 100.22 million shares outstanding. The number of shares has increased by 0.10% in one year.
| Current Share Class | 100.22M |
| Shares Outstanding | 100.22M |
| Shares Change (YoY) | +0.10% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 72.67% |
| Owned by Institutions (%) | 0.00% |
| Float | 27.07M |
Valuation Ratios
The trailing PE ratio is 17.27.
| PE Ratio | 17.27 |
| Forward PE | n/a |
| PS Ratio | 1.06 |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | 18.29 |
| P/OCF Ratio | 16.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.61, with an EV/FCF ratio of 16.56.
| EV / Earnings | 15.62 |
| EV / Sales | 0.96 |
| EV / EBITDA | 9.61 |
| EV / EBIT | 11.09 |
| EV / FCF | 16.56 |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.43 |
| Quick Ratio | 1.50 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.25 |
| Debt / FCF | 0.43 |
| Interest Coverage | 279.73 |
Financial Efficiency
Return on equity (ROE) is 13.91% and return on invested capital (ROIC) is 16.95%.
| Return on Equity (ROE) | 13.91% |
| Return on Assets (ROA) | 7.92% |
| Return on Invested Capital (ROIC) | 16.95% |
| Return on Capital Employed (ROCE) | 18.61% |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | 24.08M |
| Profits Per Employee | 1.48M |
| Employee Count | 323 |
| Asset Turnover | 1.46 |
| Inventory Turnover | 4.11 |
Taxes
In the past 12 months, Anuh Pharma has paid 175.53 million in taxes.
| Income Tax | 175.53M |
| Effective Tax Rate | 26.87% |
Stock Price Statistics
The stock price has decreased by -6.38% in the last 52 weeks. The beta is 0.47, so Anuh Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -6.38% |
| 50-Day Moving Average | 85.47 |
| 200-Day Moving Average | 79.84 |
| Relative Strength Index (RSI) | 48.59 |
| Average Volume (20 Days) | 11,514 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Anuh Pharma had revenue of INR 7.78 billion and earned 477.70 million in profits. Earnings per share was 4.76.
| Revenue | 7.78B |
| Gross Profit | 1.80B |
| Operating Income | 673.31M |
| Pretax Income | 653.24M |
| Net Income | 477.70M |
| EBITDA | 776.97M |
| EBIT | 673.31M |
| Earnings Per Share (EPS) | 4.76 |
Balance Sheet
The company has 976.33 million in cash and 194.76 million in debt, with a net cash position of 781.57 million or 7.80 per share.
| Cash & Cash Equivalents | 976.33M |
| Total Debt | 194.76M |
| Net Cash | 781.57M |
| Net Cash Per Share | 7.80 |
| Equity (Book Value) | 3.60B |
| Book Value Per Share | 35.95 |
| Working Capital | 2.74B |
Cash Flow
In the last 12 months, operating cash flow was 504.70 million and capital expenditures -53.97 million, giving a free cash flow of 450.74 million.
| Operating Cash Flow | 504.70M |
| Capital Expenditures | -53.97M |
| Depreciation & Amortization | 103.66M |
| Net Borrowing | 191.51M |
| Free Cash Flow | 450.74M |
| FCF Per Share | 4.50 |
Margins
Gross margin is 23.17%, with operating and profit margins of 8.66% and 6.14%.
| Gross Margin | 23.17% |
| Operating Margin | 8.66% |
| Pretax Margin | 8.40% |
| Profit Margin | 6.14% |
| EBITDA Margin | 9.99% |
| EBIT Margin | 8.66% |
| FCF Margin | 5.80% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 1.82%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 1.82% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | 30.98% |
| FCF Payout Ratio | 33.35% |
| Buyback Yield | -0.10% |
| Shareholder Yield | 1.72% |
| Earnings Yield | 5.79% |
| FCF Yield | 5.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 15, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Jul 15, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |